Results 81 to 90 of about 2,744,211 (203)

Hypercalcemic Crisis Induced by Hyperthyroidism of Graves' Disease: A Case Report

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Hyperthyroidism of Graves' disease (GD) is a rare but important cause of hypercalcemic crisis. In patients with hypercalcemia of unknown etiology, hyperthyroidism of Graves' disease should be considered.
Suxin Wang, Jing Wang
wiley   +1 more source

Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid

, 2014
Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer.
Chao, Ta-Chung;Chen, Dar-Ren;Chao, Tsu-Yi;Chen, Shin-Cheh;Yeh, Dah-Cherng;Wang, Hwei-Chung;Huang, Wen-Tsung;Rau, Kun-Ming;Chang, King-Jen;Yang, Tsen-Long;Lee, Kuan-Der;Tai, Cheng-Jeng;Tseng, Ling-Ming;Hou, Ming-Feng, 張金堅   +1 more
core  

Premature Occlusal Contacts Induce MRONJ in Osseointegrated Dental Implants: An Experimental In Vivo Study

Clinical Oral Implants Research, Volume 37, Issue 11, Page 1420-1430, November 2026.
ABSTRACT Objectives Medication‐related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive agents (ARAs) and can occur around well‐osseointegrated dental implants. Although implant presence–triggered osteonecrosis (IPTO) has been primarily linked to bacteria‐related peri‐implantitis, whether occlusal trauma ...
Eun‐Bin Bae, Ahana Goswami, Jun Yaung, Soo Yeon Kim, Sherry S. Baik, Kaylyn A. Yu, Chan Park, Jung‐Bo Huh, Jae‐Young Kim, Christine Y. Hong, Sol Kim, Reuben H. Kim   +11 more
wiley   +1 more source

Zoledronic Acid Induced Hepatotoxicity: A Review of Case Studies to Identify Possible Mechanisms of Toxicity

, 2020
Objectives: This study examined evidence from case studies to reinforce hepatotoxicity as a rare but serious possible adverse reaction to zoledronic acid.
Balloveras, Katherine A, Alvarez, Yamira, Levy, Arkene   +2 more
core   +1 more source

TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION

Остеопороз и остеопатии, 2013
Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR).
O V Yakushevskaya, S V Yureneva
doaj   +1 more source

Artificial Intelligence‐Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions

Orthopaedic Surgery, Volume 18, Issue 11, Page 2309-2319, November 2026.
This comprehensive review integrates 17 benchmark studies to illustrate the transition of osteoporosis management toward precision medicine. The schematic highlights three key clinical applications: AI‐driven opportunistic screening from routine CTs, precision pharmacotherapy selection, and the predictive prevention of adverse events like MRONJ ...
Xiang Yao, Yicong Chao, Xiao Gu, Jingtao Peng, Jishan Yuan, Wei Shi, Fuguo Zhang, Qiwen Bao   +7 more
wiley   +1 more source

Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism

Indian Journal of Endocrinology and Metabolism, 2017
Background: Hungry bone syndrome is a common complication of surgery for primary hyperparathyroidism in India which often leads to prolonged hospitalization. There are varying reports on the use and efficacy of bisphosphonates in the prevention of hungry
Sabaretnam Mayilvaganan, H A Vijaya Sarathi, C Shivaprasad   +2 more
doaj   +1 more source

Efficacy evaluation of denosumab in the treatment of patients with postmenopausal osteoporosis at high risk of fracture

Zhongguo Linchuang Yixue
ObjectiveTo explore the difference of efficacy and safety between denosumab and zoledronic acid in the treatment of patients with postmenopausal osteoporosis (PMOP), and to optimize the medication regimen for PMOP patients.
Jing ZHOU, Xingyun HOU, Tingting LIU, Jiaoyang ZHENG   +3 more
doaj   +1 more source

Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways

Journal of Experimental & Clinical Cancer Research, 2019
Background Zoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role on cancer stem cells (CSCs) remains unclear.
Li Wang, Yanyang Liu, Yueling Zhou, Jiantao Wang, Li Tu, Zhen Sun, Xiujie Wang, Feng Luo   +7 more
doaj   +1 more source

EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid

, 2017
Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22 ...
Yeh, Dah-Cherng;Chen, Dar-Ren;Chao, Tsu-Yi;Chen, Shin-Cheh;Wang, Hwei-Chung;Rau, Kun-Ming;Feng, Yin-Hsun;Chang, Yuan-Ching;Lee, Kuan-Der;Ou-Yang, Fu;Kuo, Wen-Hung;Chang, King-Jen;Lin, Yung-Chang;Tseng, Ling-Ming;Hou, Ming-Feng, 郭文宏;張金堅   +1 more
core